Sana Biotechnology Inc(SANA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:10 PM ET (Korea 10/28 05:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.76 | Insider Own | 37.61% | Shs Outstand | 299.3M | Perf Week | 4.66% |
| Market Cap | 0.74B | Forward P/E | - | EPS next Y | 13.71% | Insider Trans | - | Shs Float | 186.8M | Perf Month | -15.7% |
| Enterprise Value | 0.65B | PEG | - | EPS next Q | -0.15 | Inst Own | 50.97% | Short Float | 21.87% | Perf Quarter | -22.08% |
| Income | -0.21B | P/S | - | EPS this Y | 28.65% | Inst Trans | 0.19% | Short Ratio | 12.79 | Perf Half Y | -26.27% |
| Sales | 0.00B | P/B | 4.78 | EPS next 5Y | 14.37% | ROA | -53.41% | Short Interest | 40.85M | Perf YTD | -39.31% |
| Book/sh | 0.52 | P/C | 4.49 | EPS past 3/5Y | 12.33% 8.72% | ROE | -152.87% | 52W High | -56.67% ($5.70) | Perf Year | -52.95% |
| Cash/sh | 0.55 | P/FCF | - | Sales past 3/5Y | - | ROIC | -99.07% | 52W Low | 11.26% ($2.22) | Perf 3Y | -11.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.46% | Gross Margin | - | Volatility(W/M) | 5.59% 6.25% | Perf 5Y | -87.95% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.38 | EPS Q/Q | 45.3% | Profit Margin | - | RSI (14) | 40.55 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.38 | Sales Q/Q | - | SMA20 | -3.65% ($2.56) | Beta | 2.3 | Target Price | $9.38 |
| Payout | - | Debt/Eq | 0.48 | Earnings | 2026/8/10 | SMA50 | -20.65% ($3.11) | Rel Volume | 0.82 | Prev Close | $2.36 |
| Employees | 142 | LT Debt/Eq | 0.38 | EPS/Sales Surpr. | -49.76% - | SMA200 | -27.86% ($3.42) | Avg Volume(3M) | 3.19M | Price | $2.47 |
| IPO | 2021/2/4 | Option/Short | Yes/Yes | Trades | 5967 | Volume | 2,619,918 | Change | 4.66% |
🧬 Sana Biotechnology (SANA) is a US biotech company developing next-generation therapeutics based on cell engineering. With its immune evasion (Hypoimmune) platform and fusogen-based in vivo CAR-T technology as its two core platforms, it maintains a clinical-stage pipeline targeting Type 1 diabetes and immune-related and oncology diseases.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
SANA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +28.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #181 of 594 in the industry
Based on market cap of $739M.
ARDX#180 Ardelyx Inc $750M PER - SANA#181 Sana Biotechnology Inc $739M PER - 
GERN#182 Geron Corp $739M PER - 
SGMT#183 Sagimet Biosciences Inc $733M PER - 
OABI#184 OmniAb Inc $721M PER - 
FAQ
What kind of company is SANA?
SANA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SANA?
The market cap of SANA is approximately $739M, ranking 2,824 within its sector.
What is the 52-week high and low for SANA?
SANA has recorded a 52-week high of $5.70 and a low of $2.22.
